Talking Points and FAQs: Why the Food and Drug Administration Limited the Johnson and Johnson Vaccine (English, Spanish)

Talking Points and FAQs: Why the Food and Drug Administration Limited the Johnson and Johnson Vaccine (English, Spanish)

Date posted: May 18, 2022
Last reviewed: June 22, 2022

The Public Good Projects in collaboration with the Hispanic Communications Network

Talking points and FAQs provide information on the Food and Drug Administration's decision to limit the use of the Johnson and Johnson COVID-19 vaccine due to blood clot risk. The talking points emphasize that this is an example of the system working. Although blood clots are rare, regulators have determined that the availability of the Pfizer and Moderna vaccines is so high, that it is no longer necessary to give the Johnson and Johnson vaccine unless it is specifically requested or the adult cannot receive a different vaccine. The talking points also provide information on booster schedules for those who have received the Johnson and Johnson vaccine in the past. They also list the symptoms associated with blood clots for those who have received a Johnson and Johnson vaccine recently, so they can seek medical help if these symptoms develop. The FAQs cover similar information. A related graphic is available here: Social Media: Graphic About mRNA Booster Recommendation for Johnson and Johnson Vaccine Recipients (English, Spanish).

Report

Automatic translation disclaimer

El sitio web Vaccine Resource Hub proporciona una traducción automática de vaccineresourcehub.org al español, por medio del Traductor de Google. Por favor, tenga en cuenta que la versión en inglés es considerada la más precisa. En caso de desacuerdo o discrepancia entre la traducción y la versión original en inglés de este sitio web o cualquier aviso o descargo, prevalecerá la versión original.